Latest Annual Reports
by Mike Gee
09 July 2026









































ARES STRATEGIC INCOME FUND
REVENUE
$1,448,012,000
161.28%
INCOME
$781,638,000
92.47%
EMPLOYEES
N/A
CUSTOMERS
N/A
Ares Strategic Income Fund (ASIF) is a Delaware statutory trust closed-end management investment company organized as a BDC that primarily originates and invests in U.S. middle‑market credit to generate current income and long‑term capital appreciation.
View Company PageFiled: 2026-03-09
Castellum, Inc.
REVENUE
$52,866,001
18.10%
INCOME
-$2,398,292
75.97%
EMPLOYEES
244
CUSTOMERS
N/A
Castellum, Inc. is a technology services and products company providing cybersecurity, IT, electronic and information warfare, systems engineering, and mission support to U.S. defense, federal, and commercial clients.
View Company PageFiled: 2026-03-09
Circle Internet Group, Inc.
REVENUE
$2,746,642,000
63.86%
INCOME
-$69,518,000
-144.66%
EMPLOYEES
1,100
CUSTOMERS
1,000
Circle is a full‑stack, internet‑native financial platform anchored by regulated stablecoins (USDC, EURC) that provides reserve management, cross‑chain liquidity and interoperability, developer tools and the Arc blockchain, and institutional payment and custody services.
View Company PageFiled: 2026-03-09
ALX ONCOLOGY HOLDINGS INC
REVENUE
N/A
INCOME
-$101,695,000
24.59%
EMPLOYEES
43
CUSTOMERS
N/A
ALX Oncology is a clinical-stage biotechnology company developing cancer therapies (notably evorpacept and ALX2004) with no commercial products or product revenue to date.
View Company PageFiled: 2026-03-09
BETA Technologies, Inc.
REVENUE
$35,616,000
135.99%
INCOME
-$745,868,000
-170.59%
EMPLOYEES
1,008
CUSTOMERS
6
BETA Technologies is a vertically integrated electric aircraft OEM that designs, manufactures, and sells piloted CTOL and VTOL aircraft, propulsion systems, batteries, and charging/GSE solutions for civil and defense customers.
View Company PageFiled: 2026-03-09
Boundless Bio, Inc.
REVENUE
N/A
INCOME
-$58,200,000
10.96%
EMPLOYEES
N/A
CUSTOMERS
N/A
Company name not provided — a pre-revenue company that reported no revenue in 2024 or 2025 and incurred net losses of $58,200,000 in 2025 and $65,363,000 in 2024; total assets were $157,059,000 and total stockholders' equity was $98,654,000 as of 2025.
View Company PageFiled: 2026-03-09
ARS Pharmaceuticals, Inc.
REVENUE
$84,278,000
-5.46%
INCOME
-$171,298,000
-2241.76%
EMPLOYEES
106
CUSTOMERS
5
ARS Pharmaceuticals develops and commercializes neffy, a FDA- and EC-approved needle-free intranasal epinephrine product for emergency treatment of anaphylaxis, commercialized in the U.S. and internationally through direct sales and partner collaborations.
View Company PageFiled: 2026-03-09
908 Devices Inc.
REVENUE
$56,197,000
17.70%
INCOME
$19,489,000
126.99%
EMPLOYEES
172
CUSTOMERS
700
908 Devices develops and sells handheld chemical analyzers that combine miniaturized mass spectrometry with FTIR/Raman spectroscopy and machine-learning analytics to provide rapid, point-of-need identification for first responders, government, and security customers.
View Company PageFiled: 2026-03-09
Amplify Energy Corp.
REVENUE
$263,361,000
-10.63%
INCOME
$43,968,000
239.63%
EMPLOYEES
184
CUSTOMERS
3
Amplify Energy Corp is a public Delaware oil and gas company focused on acquisition, development and production of onshore and offshore oil and natural gas properties, currently concentrated on the Beta offshore (California) and Bairoil (Wyoming) assets.
View Company PageFiled: 2026-03-09
Coherus Oncology, Inc.
REVENUE
$42,172,000
59.81%
INCOME
$168,024,000
489.41%
EMPLOYEES
N/A
CUSTOMERS
N/A
A mining/minerals company that develops and sells mineral assets and related products and services, with significant research and development spending and a recent large asset sale recorded in discontinued operations.
View Company PageFiled: 2026-03-09
Cartesian Therapeutics, Inc.
REVENUE
N/A
INCOME
-$130,302,000
-68.30%
EMPLOYEES
75
CUSTOMERS
N/A
Cartesian Therapeutics is a late-stage biotechnology company developing autologous, mRNA-modified CAR-T cell therapies for autoimmune diseases, with lead candidate Descartes-08 targeting myasthenia gravis and in-house cGMP manufacturing.
View Company PageFiled: 2026-03-09
AMERICAN COASTAL INSURANCE Corp
REVENUE
$335,439,000
13.07%
INCOME
$106,837,000
41.10%
EMPLOYEES
N/A
CUSTOMERS
N/A
Holding company primarily engaged in U.S. commercial property and casualty insurance through principal operating subsidiary American Coastal Insurance Company (AmCoastal), focused on Florida catastrophe-exposed commercial property (condominiums, apartments, assisted living); renamed from United Insurance Holdings Corp. on July 10, 2023.
View Company Page